ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/22/2023
Back to search
Official data from USPTO
HITMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HITMAB
ST13
US500000079316062Class
5, 35, 42
Filing
79316062
Registration
6854569
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
09/22/2023
Trademark type
Word
Nice classes
5, 35, 42
Filing date
04/26/2021
Registration date
09/27/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/27/2022
Last transaction
09/27/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CN
Examiner
HUSSAIN, TASNEEM
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Zhuhai Trinomab Pharmaceutical Co., Ltd.
TRINOMAB BIOTECH CO., LTD
Representatives
Scot A. Duvall Middleton Reutlinger
Technical classification
Nice Classes
Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vaccines; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; pharmaceutical preparations for the prevention and treatment of HIV/AIDS; pharmaceutical preparations for the prevention and treatment of liver diseases; pharmaceutical preparations for the prevention and treatment of respiratory system disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseasesdiabetes; pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of viral and infectious diseasesblood disorderspaininflammationsepsisalopeciaobesitycancertumors and cognitive disorders; drugs for medical purposes for the prevention and treatment of HIV/AIDS; drugs for medical purposes for the prevention and treatment of liver diseases; drugs for medical purposes for the prevention and treatment of respiratory system disorders; drugs for medical purposes for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases and diabetes; drugs for medical purposes for the prevention and treatment of gastro-intestinal diseases; drugs for medical purposes for the prevention and treatment of immune system related diseases and disorders; drugs for medical purposes for the prevention and treatment of viral and infectious diseasesblood disorderspaininflammationsepsisalopeciaobesitycancertumors and cognitive disorders; biological preparations for medical purposes for the prevention and treatment of HIV/AIDS; biological preparations for medical purposes for the prevention and treatment of liver diseases; biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; biological preparations for medical purposes for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases and diabetes; biological preparations for medical purposes for the prevention and treatment of gastro-intestinal diseases; biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; biological preparations for medical purposes for the prevention and treatment of viral and infectious diseasesblood disorderspaininflammationsepsisalopeciaobesitycancertumors and cognitive disorders; medicines for human purposes for the prevention and treatment of HIV/ AIDS; medicines for human purposes for the prevention and treatment of liver diseases; medicines for human purposes for the prevention and treatment of respiratory system disorders; medicines for human purposes for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases and diabetes; medicines for human purposes for the prevention and treatment of gastro-intestinal diseases; medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; medicines for human purposes for the prevention and treatment of viral and infectious diseasesblood disorderspaininflammationsepsisalopeciaobesitycancertumors and cognitive disorders; chemico-pharmaceutical preparations for the treatment of viral and infectious diseasesimmune system related diseasescancertumors and inflammation; chemical preparations for pharmaceutical purposes for the treatment of viral and infectious diseasesimmune system related diseasescancertumors and inflammation
Class 35
Retail store services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services featuring pharmaceuticalveterinary and sanitary preparations and medical supplies
Class 42
Biological research; research and development of new products for others; scientific laboratory services; scientific research; chemical analysis; conducting clinical trials for others; technological research in the fields of medicinethe preventiontreatment and management of illnesshealth care delivery; technological research in the fields of geneticsgenetic engineeringmolecular biology and cellular immunology; conducting technical scientific feasibility project studies; chemistry servicesconsultationresearch and advice; chemical research
Publications
History of USPTO decisions and trademark events.
32 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/07/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/18/2023
FIMP
FINAL DISPOSITION PROCESSED
01/18/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/27/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/27/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/27/2022
GPNX
NOTIFICATION PROCESSED BY IB
07/18/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/12/2022
PUBO
PUBLISHED FOR OPPOSITION
07/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/29/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/29/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/22/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/06/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
06/06/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/06/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
06/06/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/06/2022
DMCC
DATA MODIFICATION COMPLETED
06/03/2022
ALIE
ASSIGNED TO LIE
06/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/25/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/24/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/24/2022
RFNT
REFUSAL PROCESSED BY IB
02/06/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/18/2022
RFRR
REFUSAL PROCESSED BY MPU
01/18/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/28/2021
CNRT
NON-FINAL ACTION WRITTEN
12/27/2021
DOCK
ASSIGNED TO EXAMINER
12/22/2021
MAFR
APPLICATION FILING RECEIPT MAILED
07/27/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/23/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/22/2021
Continuous trademark protection
Get notified about every new filing that threatens HITMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.